Publication: Editorial: Resistance to Medical Therapy in Pituitary Tumors.
Loading...
Identifiers
Date
2022-01-31
Authors
Auriemma, Renata S
Gahete, Manuel D
Gatto, Federico
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Research Foundation
Abstract
Pituitary tumors may exhibit resistance to conventional medical treatments, including somatostatin receptor (SST) ligands (SRLs) and dopamine agonists (DAs) (1, 2). Resistance to medical treatment leads to multi-modal therapies, including surgery and radiotherapy. However, treatment-resistant tumors frequently relapse after radical surgical excision. This is of crucial interest as it occurs in a considerable proportion of patients with pituitary tumors (3). Indeed, resistance to conventional treatments is nowadays considered a predictive factor of the aggressive behavior of the pituitary tumor, being associated with poor prognosis and increased mortality. Predictors of responsiveness to medical treatments are still under investigation, and there is no clear evidence for the best individualized medical therapy in patients with aggressive pituitary lesions
Description
MeSH Terms
Pituitary neoplasms
Dopamine agonists
Receptors, somatostatin
Pituitary diseases
Chronic disease
Prognosis
Dopamine agonists
Receptors, somatostatin
Pituitary diseases
Chronic disease
Prognosis
DeCS Terms
Agonistas de dopamina
Enfermedad crónica
Enfermedades de la hipófisis
Neoplasias hipofisarias
Pronóstico
Receptores de somatostatina
Enfermedad crónica
Enfermedades de la hipófisis
Neoplasias hipofisarias
Pronóstico
Receptores de somatostatina
CIE Terms
Keywords
Adenomas, Dopamine receptors, Pituitary, Resistance, Somatostatin receptors, Tumors
Citation
Auriemma RS, Gahete MD, Gatto F. Editorial: Resistance to Medical Therapy in Pituitary Tumors. Front Endocrinol (Lausanne). 2022 Feb 23;13:861230